课题基金 / 基金详情

STICH TRIAL - NEUROHORMONAL/ CYTOKINE/ GENETIC CORE LAB

STICH TRIAL - NEUROHORMONAL/ CYTOKINE/ GENETIC CORE LAB
STICH 试验 - 神经激素/细胞因子/遗传核心实验室
批准号:
7497233
负责人:
ARTHUR M FELDMAN
金额:
$4.68万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-30 至 2009-12-31

项目摘要

项目成果

ARTHUR M FELDMAN的其他基金

相似基金

相关文献

中文摘要
翻译
缺血性心力衰竭的外科治疗(ST1CH)多中心国际随机试验解决了两个特定的
英文摘要
The Surgical Treatment for Ischemic Heart Failure (ST1CH) multicenter international randomized trial addresses two specific primary hypotheses in patients with clinical heart failure (HF) and left ventricular (LV) dysfunction who have coronary artery disease (CAD) amenable to surgical revascularization: 1) Coronary artery bypass grafting (CABG) with intensive medical therapy (MED) improves long-term survival compared to intensive medical therapy alone; 2) In patients with regional LV dysfunction, surgical ventricular restoration (SVR) to a more normal LV size and shape improves survival free of subsequent hospitalization in comparison to CABG alone. Important secondary endpoints reflecting morbidity, cost, and quality of life will be assessed. Core laboratories for cardiac magnetic resonance (CMR), echocardiography (ECHO), neurohormonal/cytokine/genetic (NCG), and radionuclide (RN) studies will ensure consistent testing practices and standardization of data necessary to identify eligiblepatients and address specific questions related to the primary hypotheses. Over three years, 50 clinical sites will recruit 2,800 consenting patients with HF, LV ejection fraction (EF) < .35, and CAD amenable to CABG. These patients first will be characterized by angina intensity or presence of left main coronary stenosis as appropriate for only surgical therapy or both medical and surgical therapy. AH patients will be evaluated further for appropriateness of SVR indicated by an end-systolic volume index (ESVI) > 60 ml/m2 and dysfunction in a single LV region. The 600 patients estimated to be eligible for SVR but ineligible for randomization to medical therapy will be evenly randomized to CABG with or without SVR. Of the 2,200 consenting patients eligiblefor medical or surgical therapy, the 1,600 not SVR eligiblewill be evenly randomized between MED only and MED with CABG. The remaining600 patients also eligible for SVR will be evenly randomized between three treatments of MED only, or MED + CABG, or MED + CABG + SVR. Registries of clinical information will be maintained on patients who are eligible but decline trial entry. AHrandomized and some registry patients will be followed by a clinic visit at four-month intervals for a minimum of three years. Appropriate subgroups of randomized patients will have core laboratory studies repeated at specified follow-up intervals. The neurohormone/cytokine/genetic core will test three hypothesis: 1) pre-operative levels of neurohormones, natriuretic peptides, and pro-inflammatory cytokines will be useful in predicting that group of patients who will most likely benefit from either surgical revascularization and/or surgical revascularization with SVR; 2) salutary changes post-operatively in neurohormonal/cytokine/natriuretic peptide activation will predict long term outcomes in patients undergoing either surgical revascularization and/or revascularization with SVR and will provide the physiologic rationale for these changes; and 3) patients having a favorable genotype (eg.Low expression of ACE gene or high levels of adenosine) will be most likely to achieve long-term benefit from either CABG or CABG with SVR.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1161/circulationaha.121.056276
发表时间: 2022-03-15
期刊: Circulation
影响因子: 37.8
作者: [Chew DS, Cowper PA, Al-Khalidi H, Anstrom KJ, Daniels MR, Davidson-Ray L, Li Y, Michler RE, Panza JA, Piña IL, Rouleau JL, Velazquez EJ, Mark DB, STICH Investigators]
通讯作者: STICH Investigators
DOI: 10.1056/nejmoa1100358
发表时间: 2011-04-28
期刊: The New England journal of medicine
影响因子: --
作者: [Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA, Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA, STICH Trial Investigators]
通讯作者: STICH Trial Investigators
DOI: 10.1159/000368221
发表时间: 2015
期刊: Cardiology
影响因子: 1.9
作者: [Feldman AM, She L, McNamara DM, Mann DL, Bristow MR, Maisel AS, Wagner DR, Andersson B, Chiariello L, Hayward CS, Hendry P, Parker JD, Racine N, Selzman CH, Senni M, Stepinska J, Zembala M, Rouleau J, Velazquez EJ, Lee KL]
通讯作者: Lee KL
The emerging role of pharmacogenomics in the treatment of patients with heart failure.
药物基因组学在心力衰竭患者治疗中的新兴作用。
DOI: 10.1016/j.athoracsur.2003.09.004
发表时间: 2003
期刊: The Annals of thoracic surgery
影响因子: --
作者: [Feldman,ArthurM]
通讯作者: Feldman,ArthurM
6
    Role of Adenosine Receptors in Cardiac Failure and Protection
    • 批准号:
      8241982
    • 项目类别:
    • 资助金额:
      $28.92万
    • 财政年份:
      2011
    • 负责人:
      ARTHUR M FELDMAN
    • 依托单位:
    Role of Adenosine Receptors in Cardiac Failure and Protection
    • 批准号:
      8150070
    • 项目类别:
    • 资助金额:
      $49.86万
    • 财政年份:
      2010
    • 负责人:
      ARTHUR M FELDMAN
    • 依托单位:
    Role of Adenosine Receptors in Cardiac Failure and Protection
    • 批准号:
      7488121
    • 项目类别:
    • 资助金额:
      $49.93万
    • 财政年份:
      2008
    • 负责人:
      ARTHUR M FELDMAN
    • 依托单位:
    STICH TRIAL - NEUROHORMONAL/ CYTOKINE/ GENETIC CORE LAB
    • 批准号:
      6701779
    • 项目类别:
    • 资助金额:
      $2.51万
    • 财政年份:
      2002
    • 负责人:
      ARTHUR M FELDMAN
    • 依托单位:
    国内基金
    海外基金
    基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
    • 批准号:
      82074359
    • 项目类别:
      面上项目
    • 资助金额:
      55.0万元
    • 批准年份:
      2020
    • 负责人:
      安晓飞
    • 依托单位:
    细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
    Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制